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Purpose of the study
Controversial data have been recently published with
respect to the antiviral response to abacavir(ABC)/lamivu-
dine(3TC) (Kivexa®). We compared the efficacy and safety
of efavirenz(EFV)+abacavir(ABC)/lamivudine(3TC)
(Kivexa®) with other conventional regimens of
2NRTI+efavirenz(EFV).
Methods
A multicenter, prospective and randomized study was per-
formed in 19 centres located in Spain (18) and Italy (1).
Patients in treatment with 2NRTI+EFV and viral suppres-
sion over ≥6 months were randomized to ABC/3TC
(Kivexa®)+ EFV (Group A) or to continue the same regi-
men 2NRTI+EFV (Group B) and followed every 3 months
until 48 weeks. Mann-Whitney test (non-parametric test)
was used to compare between continuous variables.
Summary of results
A total of 100 patients were included in this study: 51 of
them in Group A and 49 in Group B. Both groups were
comparable for all baseline variables. Only one patient
from Group A presented viral rebound at 24 weeks. No
statistically significant changes from baseline in CD4+ cell
count were seen at week 48 in either group: 528 cell/mm3
(± 252) to 592 (± 266) in Group A and 644 (± 265) to 627
(± 224) in Group B, (p = 0.311 between groups) at week
48. Total cholesterol showed a slight increase only at week
24 in Group A (from 198 mg/dl ± 43 to 214 ± 39, p =
0.014) and in Group B (200 mg/dl ± 50 to 194 ± 53; p =
0.036) without any difference at week 48. Drug discontin-
uation for toxicity was higher in Group A (seven subjects
(7%), five of them for hypersensitivity reaction) than in
Group B (only two patients).
Conclusion
ABC/3TC (Kivexa®), in combination with EFV, was a good
alternative as a simplification regimen due to its virologi-
cal and immunological effectiveness and good tolerabil-
ity. Nowadays, the availability of a genetic test (HLA
B*57) will reduce the incidence of discontinuation due to
hypersensitivity reaction.
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